SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review

J Neuroimmunol. 2017 Mar 15:304:29-34. doi: 10.1016/j.jneuroim.2016.07.007. Epub 2016 Jul 17.

Abstract

Neurodegeneration is an important determinant of disability in multiple sclerosis (MS) but while currently approved treatments reduce inflammation, they have not been shown to reduce neurodegeneration. SIRT1, a NAD dependent protein deacetylase, has been implicated in the pathogenesis of neurodegeneration in neurological diseases including MS. We have studied the role of SIRT1 in experimental autoimmune encephalomyelitis (EAE) and found evidence for a neuroprotective role. In this review we summarize the most recent findings from the use of SIRT1 activators and SIRT1 overexpression in transgenic mice. These data support provide a rational for the use of SIRT1 activators in MS.

Keywords: EAE; Multiple sclerosis; NAD; Neurodegeneration; SIRT1.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy
  • Encephalomyelitis, Autoimmune, Experimental / metabolism
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / metabolism*
  • NAD / biosynthesis*
  • Sirtuin 1 / biosynthesis*

Substances

  • Immunosuppressive Agents
  • NAD
  • SIRT1 protein, human
  • Sirtuin 1